CLINICAL TRIALS AND OBSERVATIONS Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
نویسندگان
چکیده
*Thorsten Braun,1 *Raphael Itzykson,1,2 Aline Renneville,3 Benoit de Renzis,4 François Dreyfus,5 Kamel Laribi,6 Krimo Bouabdallah,7 Norbert Vey,8 Andrea Toma,9 Christian Recher,10 Bruno Royer,11 Bertrand Joly,12 Anne Vekhoff,13 Ingrid Lafon,14 Laurence Sanhes,15 Guillaume Meurice,2 Cédric Oréar,2 Claude Preudhomme,3 Claude Gardin,1 Lionel Ades,1 Michaela Fontenay,16 Pierre Fenaux,1 Nathalie Droin,2 and Eric Solary2 on behalf of the Groupe Francophone des Myélodysplasies
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic activity of epigenetic priming with decitabine before standard induction chemotherapy in patients with less-thanfavorable risk of acute myelogenous leukemia (AML). We directly compared the clinical and DNA-hypomethylating activity of decitabine delivered at 20 mg/m2 by either a 1-hour infusion (Arm A) or a ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic re...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase
In chronic myelogenous leukemia (CML) imatinib mesylate has been shown to selectively inhibit the tyrosine kinase domain of the oncogenic bcr-abl fusion protein. Using this agent alone high rates of cytogenetic responses were recorded. However, several mechanisms of resistance have been described. In vitro studies examining the effects of imatinib mesylate plus cytarabine have shown synergistic...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio, Juan Luis Steegmann, Neil P. Shah, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiřı́ Mayer, Jorge Cortes, Michele Baccarani, Dong-Wook Kim, M. Brigid Bradley-Garelik, Hesham Mohamed, Mark Wildgust, and And...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome–positive chronic myeloid leukemia after failure of interferon-
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronicphase CML after failure on interferonwere treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 mon...
متن کامل